brazil jv

“ADVANTAGE” IN BRAZIL

Copyright 2009 MANAS KANUNGO 1

A SUCCESS STORY:

Eli Lilly & Boehringer Mannheim JV

AUG `96 - DEC `99

Brazil: Lilly / Roche (BMC) Business Results

BACKGROUND

BOEHRINGER MANNHEIM Corp (BMC) & ELI LILLY HAD BOTH IDENTIFIED

Copyright 2009 MANAS KANUNGO 2

BRAZIL AS A PRIORITY COUNTRY w/ SIGNIFICANT GROWTH POTENTIAL.

BASED ON THE GLOBAL MARKETING ALLIANCE EXISTING IN 1996, BOTH

COMPANIES DECIDED TO INVEST IN A JOINT 5-YEAR AGREEMENT

TO DEVELOP THE DIABETES BUSINESS IN BRAZIL.

Brazil: Lilly / Roche (BMC) Business Results

BACKGROUND

• PROJECT FORMALLY BEGAN EARLY `96, AND LAUNCHED IN AUG `96

• A NEW DIABETES CARE DEPARTMENT WAS FORMED WITHIN LILLY BRAZIL

Copyright 2009 MANAS KANUNGO 3

• BOTH MAINTAINED SHARED & SPECIFIC MARKETING RESPONSIBILITIES

• BOTH COMPANIES SHARED A COMMON SALES FORCE

• TEAM PROMOTED THE COMPLETE PORTFOLIO OF DIABETES PRODUCTS

- ORAL TABLETS, URINE STRIPS, INSULIN, MONITORING SYSTEM

Brazil: Lilly / Roche (BMC) Business Results

BACKGROUND

THE ALLIANCE WAS TERMINATED OCT `31ST, `98, DUE TO ACQUISITION OF

Copyright 2009 MANAS KANUNGO 4

CORANGE / BOEHRINGER MANNHEIM BY HOFFMAN LA ROCHE.

MONITORING BUSINESS FROM ASTA MEDICA & LILLY WERE TRANSFERRED

TO NEWLY FORMED PATIENT CARE BUSINESS UNIT OF ROCHE DIAGNOSTICS

BRAZIL IN JULY & NOV `98 RESPECTIVELY.

Brazil: Lilly / Roche (BMC) Business Results

RELEVANT DEMOGRAPHICS - BRAZIL

• POPULATION: 160 MM > 15% UNEMPLOYED

Copyright 2009 MANAS KANUNGO 5

• 250K TOTAL MDs; 150K GPs; 2K ENDOs; 250K NURSES; NO DNEs

• 75K PHARMACISTS; 50K PHARMACIES INCL. 35 SPECIALIZED PHARMACIES

• 6,500 HOSPITALS: PRIVATE, FEDERAL, STATE, MUNICIPAL

Brazil: Lilly / Roche (BMC) Business Results

DIABETICS - BRAZIL

• 7.6% DIABETICS

• 2.5MM UNDIAGNOSED

Copyright 2009 MANAS KANUNGO 6

• 2.5MM UNDIAGNOSED

• 0.5MM BEING TREATED WITH INADEQUATE / UNACCEPTABLE THERAPIES

• 22.3% OF DIAGNOSED GET NO TREATMENT

• 40.7% ARE ON ORAL AGENTS

• 29.1% ARE ON DIETETIC TREATMENT

• 7.9% ARE ON INSULIN THERAPY

FINANCIAL, MARKET DEMOGRAPHICS: `96 - `98

• 10% - 15% OF EMPLOYED POPULATION WITH DISPOSABLE INCOME

• VERY HIGH BUT RELATIVELY STABLE:

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 7

IMPORT DUTIES CORP / SALES TAXES

INTEREST RATES INFLATION

• MINIMAL GOVERNMENT REIMBURSEMENT AND INSURANCE COVERAGE

TILL JULY ‘96: BAYER ONLY COMPANY w/MONITORING PRODUCTS, > 70% SHARE

BIOBRAS, NOVO, SOME LILLY INSULIN

LOCAL $ALES (x$ MM)

7.8

9.3

7

8

9

10

Humulin

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 8

1.40.7

2.1

4.5

3.1 3.3

0

1

2

3

4

5

6

7

96 97 98 99*

Advantage

*Est $ = R$ 1.80

Lilly $ Share Est = 32%

HUMULIN UNIT SALES

432

700

500

600

700

Units x1000

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 9

181

291

432

0

100

200

300

400

500

96 97 98 99* *Forecast

HUMAN INSULIN IMS SHARES - UNITS

53.1%

45.3%42.3%50.0%

60.0% Lilly Novo Biobras

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 10

22.4%24.5% 26.6%

28.2% 28.8% 29.0%

0.0%

10.0%

20.0%

30.0%

40.0%

96 97 98

ADVANTAGE® ORIGINAL vs ACTUAL LOCAL SALES (x$ MM)

10

13

18

12

14

16

18 Orig.Frcst. Actual Tot. Mkt.

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 11

0.5 0.7

10

3.64.5

6.3

7.8

0

2

4

6

8

10

12

96 97 98

Aug - Dec

12 Mnth

12 Mnth

12 Mnth

ADVANTAGE MARKET SHARE

34%

43%

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 12

7%

'96 '97 '98

MONOTORING COMPANIES - $MM & SHARES ‘98

7.3

5.3

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 13

41% 29%

2.5

14%

1.5

8%

1.4

8%0.5

3%

Adv/Lily Bayer Abbott Roche Asta Others

TOTAL BM / ROCHE vs OTHERS - $MM & SHARES ‘98

10.2

Total Roche = Adv / Lilly 7.3 + Roche 1.5 + Asta 1.4

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 14

57%

5.3

29%

2.5

14% 0.53%

Tot. Roche Bayer Abbott Others

ADVANTAGE METERS & KITS UNITS SOLD

36779

28366

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 15

44753900 4500 5000

1996 1997 1998

Original

Actual

ADVANTAGE METERS & KITS $ALES & AUP

‘96 ‘97 ‘98

TOT $ Orig 160K 200K 200K

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 16

Actual 290K 855K 1,169K

KITS AUP Orig 42.24 43.29 45.45

Actual 73.21 73.81 76.57

METER AUP Orig 0 2.85 3.00

Actual 28.47 1.88 20.11

ADVANTAGE EQUIV. VIALS ‘50 UNITS (X000) SOLD

200

160

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 17

10.910.5

102

85

1996 1997 1998

Original

Actual

ADVANTAGE STRIPS $ALES & AUP

‘96 ‘97 ‘98

TOT $ Orig 260K 3,200K 5,800K

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 18

Actual 395K 3,399K 6,279K

‘25 AUP Orig 16.25 14.41 15.59

Actual 18.95 17.05 16.50

‘50 AUP Orig 30.97 32.25 33.81

Actual 35.78 32.78 30.76

ADVANTAGE % SALES IN MAJOR SEGMENTS

72.0%69.5%

74.5%

Retail

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 19

27.0%30.5%

25.5%

'96 '97 '98

Hospital

ADVANTAGE $MM SALES IN MAJOR SEGMENTS

5.8

Retail

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 20

0.50.2

3.1

1.4

2.0

'96 '97 '98

Hospital

1998 ADVANTAGE % $ALES IN ALL SEGMENTS

Govt. Hosp

7%Distrib.

11%

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 21

Sp. Pharm

48%

Priv. Hosp

18%

Chains

16%

KEY SUCCESS FACTORS

1. ALL THREE PLAYERS - BM, LILLY, MARKET, WERE READY & COULD GROW

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 22

2. AN ALLIANCE DEDICATED FOR DIABETES with a COMPLETE PORTFOLIO

3. RAISING EVERYONE’S LEVEL OF AWARENESS, EDUCATION (H-J), TRAINING(see separate presentation on this initiative)

KEY SUCCESS FACTORS

4. GIVING CUSTOMERS WHAT THEY NEEDED MOST:

ATTENTION

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 23

ATTENTION

FREQUENT VISITS, PARTNERSHIP IN THEIR EVENTS, ENHANCE THEIR KNOWLEDGE (H-J)

HELP THEM DO THEIR JOB BETTER

TOOLS FOR PATIENT USE: MATERIALS FOR EDUCATION, TRAINING, CONTROL

PRODUCT THEY COULD RELY ON

QUALITY, AVAILABILITY, TIMELY DELIVERY, PRICE, SERVICE, SUPPORT, HELP DESK

KEY SUCCESS FACTORS

5. THE TEAM’S COMMITTMENT FOR EFFECTIVE, LONG-TERM RESULTS:

Brazil: Lilly / Roche (BMC) Business Results

Copyright 2009 MANAS KANUNGO 24

BUILDING AWARENESS & RECOGNITION VIA MEDIA, PROF. SOCIETIES, CONGRESSES

HARVARD - JOSLIN - SBD EDUCATION & TRAINING PROGRAM FOR ENDOs, GPs, EDUCATORS *

CLOSED - LOOP, PRIORITIZED, VALUE BASED PROGRAMS & PROMOTIONS

* Please see separate presentation on this initiative.